Stifel Reiterates Buy Rating on Eliem Therapeutics (ELYM), Sees Positive Risk/Reward Ahead of Upcoming ETX-810 Readouts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| (NASDAQ: ELYM) | Delayed: 5.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.11 | 52 Week High | $ | |||
| Open | $5.11 | 52 Week Low | $ | |||
| Day High | $5.11 | P/E | N/A | |||
| Day Low | $5.11 | EPS | $ | |||
| Volume | 37,649 | |||||
